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History of Phage Therapy
During the cholera epidemics in 19th century India, 
around 20 million people lost their lives. Those who drank 
water or swam in the Ganges rarely contracted cholera1. 
Hindu ritual baths take place in the Ganges River which, 
due to the monsoons, contains large quantities of phages 
from the ground. Although in the Hindu world the purpose 
of these baths is a physical and spiritual purification, their 
primary effect is therapeutic. In 1896, British bacteriolo-
gist Ernest Hanbury Hankin showed that water from the 
Ganges and Yamuna rivers contain some biological sub-
stance which destroys cholera cultures. It could pass 
through the Millipore filters which retained larger micro-
organisms such as bacteria2. Two years later, Russian 
microbiologist Gamaley noticed a similar phenomenon3. 
However, it was not until 20 years later that Frederick 
Twort confirmed that the substance which passes through 
the filter can completely break bacteria, but cannot grow 
in their absence4. Twort described it as a substance se-
creted by microorganisms for a purpose unknown at the 
time5,6. Twort’s results were published in 1915 in The Lan-
cet journal which is why the discovery of bacteriophage is 
connected with his name7. Twort’s work in The Lancet 
reminded Felix d’Herelle of his previous research con-
ducted in Mexico and Tunis on treating the plague-infect-
ed locusts8. D’Herelle conducted the first application of 
bacteriophage as medication on soldiers who suffered from 
bacillary dysentery6,9,10. Even the name ‘bacteriophage’ 
was suggested by d’Herelle, a combination of the word 
‘bacteria’ and the Greek ‘phagein’ meaning to eat. 
D’Herelle believed that bacteriophages are viruses which 
destroy bacteria. His contribution is also evident due to 
the foundation of several centers for treatment via bacte-
riophage 11. For his idea of treating humans and animals 
against various bacterial diseases with bacteriophages, 
he was nominated for a Nobel Prize eight times but was 
sadly never awarded8.
Although d’Herelle’s treatments of patients with bacte-
riophages conducted in a hospital in Paris were very suc-
cessful, they were not immediately published12. The first 
published study of bacteriophage treatment dates from 
1921 when Richard Bruynoghe and Joseph Maisin an-
nounced that they used bacteriophage in the treatment of 
staphylococcal skin infection13. The treatment’s positive 
results provided an incentive for additional research. All 
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of this also prompted a few companies to start producing 
phages commercially and to continue to use them to treat 
various bacterial infections. D’Herelle’s laboratory situ-
ated in Paris produced five different phage preparations 
whose purpose was to treat bacterial infections6. In Po-
land, which also leads the way in bacteriophage research 
and application to treat humans today, the firsts cases of 
phage therapy were recorded in 1926/1927 at the Jagiel-
lonian University Medical College Clinic of Surgery in 
Krakow 10,14.  Despite criticism, research was continued at 
an institute in Wroclaw, today known as The Institute of 
Immunology and Experimental Therapy PAS in Wroclaw15. 
The Soviet Union used phage therapy during the Second 
World War when it was effectively used to treat soldiers8,16. 
Since then in Georgia, a former Soviet Union Republic, 
phages have been used intensively and with some success-
ful results at the George Eliava Institute in Tbilisi, Geor-
gia. Currently, the Institute has accomplished impressive 
results in the treatment of wounds and bedsores, ulcers, 
burns, and purulent osteomyelitis. Phage preparations can 
also be bought in their pharmacy and used to treat infec-
tions caused by Streptococcus, Escherichia coli, and Pseu-
domonas17–19. Phage intended for therapeutic treatments 
were also produced in the United States of America. In 
1940, the Eli Lilly and Co. company produced seven phage 
preparations intended for human use6,20.
The majority of early bacteriophage research was based 
on preventing bacterial infections10 and were conducted in 
the former Soviet Union or Poland. It was not until the end 
of the 1980s that bacteriophages were discovered ‘again’ 
and research on animals started21,22. Research on humans 
began in the 2000s. Results of the first phase of random-
ized clinical research carried out with bacteriophage in the 
USA were published in 200923.
Emergence of Antibiotics
By imitating the relations in microbiocenosis, complex 
pharmaceutical products were created – drugs that in very 
small doses and concentrations suppress or destroy patho-
gens in humans and animals. They are called antibiotics, 
and their mechanisms of action includes: damaging the cell 
wall, disabling production of essential bacterial protein, 
blocking transporting cell wall’s mechanism, blocking cell 
reproduction, blocking bacterial enzymes, etc.24,25. Antibi-
otics are drugs that are selectively toxic to bacteria, and 
nontoxic or acceptable toxic for the host’s organism. 
The founder of modern antimicrobial therapy is Alex-
ander Fleming who in 1928 published his research on 
growth inhibition of Staphylococcus aureus on a feeder 
contaminated with molds Penicillium notatum. The dis-
covery of penicillin was followed by the discovery of sul-
phonamide in 1932, streptomycin in 1943, chloramphenicol 
in 1946, erythromycin in 1948, vancomycin in 1953, ri-
fampin in 1957, ciprofloxacin in 1961, daptomycin in 1986, 
bedaquiline in 199724.
More than 4000 antibiotics were isolated from micro-
bial sources, and more than 30000 synthetic and semi-
synthetic ones were produced by natural origins (of same 
or similar compositions and operating principles). In clini-
cal practice only about 100 various antibiotics are used 
because of the harmful consequences they provoke in the 
patients or because their wider usage would be too expen-
sive26,27. Therefore, the theoretical value of antibiotics de-
pends only upon their activity, i.e., their efficiency, speed, 
simplicity, availability, and safety which can fall within 
these characteristics: selective toxicity (bacterial cell ver-
sus host cell), therapeutic ration, tolerance, pharmacoki-
netics, and pharmacodynamics28. Antibiotics are divided 
according to their mode of operation, effect, mechanism of 
action, and chemical composition. 
Antibiotics had soon become an irreplaceable cure for 
an increasingly large number of bacterial diseases while 
research and creation of new antibiotics promised a care-
free future24. However, already after twenty years of the 
systematic antibiotic application, it was noted that infec-
tions with some agents responsible for diseases (gram 
positive and gram negative bacteria) could not be overcome 
with existing antibiotics anymore, and synthesis of new, 
mostly selective antibiotics ensued29. Combinations or al-
ternative antibiotics were used, which led to panic at the 
end of the last century. In fact, some types of bacteria, 
using their genome which was upgraded during billions of 
years, create resistance against the most commonly used 
antibiotics, and soon afterward against all available ones26.
Countless attacks, both biological and environmental, 
‘teach’ the bacteria which then create a resistance mecha-
nism against most antibiotics by producing new proteins 
which block the antibiotics or repair damaged systems in 
the cytoplasm, and can also change cell wall structure as 
the first line of defense (the most effective barrier). There-
fore, bacterial resistance and understanding its mecha-
nisms becomes the subject of study while new antibiotics 
are synthesized simultaneously30,31.
Resistance may be natural, i.e., permanently displayed 
through the ‘wild’ phenotype, or acquired, displayed 
through mutations or new gene acquisition24. The inher-
ited – natural resistance is exhibited by bacteria by mak-
ing it more difficult for antibiotics to enter the gram-nega-
tive cell of a bacteria. In that way, lipopolysaccharide 
membranes stop the entry of penicillin 6, macrolides, and 
vancomycin while some inactivate antibiotics via bacterial 
enzymes (e.g., Klebsiella which has beta-lactamase). An 
example of natural resistance is the absence of affinity 
between antibiotics and the target location or the absence 
of the target location. Therefore mycoplasmas, which do 
not have a cell wall, are resistant to beta-lactamase, anti-
biotics which influence cell wall synthesis32.
Acquired resistance is far more dangerous than the 
natural since it exhibits little known mechanisms which 
bacteria can develop, including gene modification. Cross-
resistance is the simultaneous resistance to all antibiotics 
in the same group (e.g., all beta-lactamase antibiotics)33. 
Multiple resistance is a resistance to various groups of an-
tibiotic combinations of several different and independent 
resistance mechanisms25,34.
Bacteria develop acquired resistance through horizon-
tal and vertical gene transfer, and recombination mecha-
nisms. Horizontal gene transfer is a direct transfer of ge-
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netic material between biologically unrelated species, 
while in the vertical gene transfer genetic material passes 
from the parents to their daughter’s cells. Gene recombina-
tion mechanism, when bacteria exchange genes via third 
parties, can occur between two bacteria by the process of 
transformation, conjugation, and transduction. By recom-
bination, bacteria acquire new genes and therefore become 
resistant to antibiotics they have never been treated with. 
Especially ‘dangerous’ way of gene transfer is conjugation, 
i.e., gene transfer during sexual reproduction (copulation) 
between different species of bacteria (parts of plasmids 
being transferred)25,35. Therefore, bacteria acquire new 
genes which can produce or enhance resistance to antibiot-
ics they never had direct contact with.
Because of all this, in the 21st century antibiotics can 
be as efficient with treating and stopping the spread of con-
tagious bacterial diseases as they were two centuries ago. 
More and more multiresistant species appear making like-
ly that even the most simple operations may become fatal 
because of postoperative infection with the aforementioned 
multiresistant bacteria34. The most dangerous types may 
be both gram-positive and gram-negative bacteria: Pseudo-
monas aeruginosa, Mycobacterium tuberculosis, Penicillin 
resistant, Streptococcus spp (PRSP), methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin-resistant, En-
terococcus (VRE), extended-spectrum beta-lactamases bac-
teria (ESBLs). However, the biggest danger lies in the re-
sistance of gram-negative (intestinal bacteria) against 
carbapenems: imipenem, meropenem, ertapenem36. 
Apart from the aforementioned large problems regard-
ing antibiotics (except increasingly larger bacteria resis-
tance), the frequent implementation of inadequately re-
searched or tested antibiotics brings about new dangers. 
This is why FDA (Federal Agency of the United States) 
notes that there is a real danger of antibiotics (ciprofloxa-
cin, ofloxacin, norfloxacin, gemiloxacin, moxifloxacin and 
others) with regard to the permanent nerve, kidney, and 
eye damage; while fluoroquinolones present a risk for chil-
dren, senior citizens, and pregnant women37. It is therefore 
obvious that bacteria have a genetic potential and resis-
tance mechanisms against antibiotics because they have 
encountered similar attacks during their evolution, which 
resulted in the development of new defense mechanisms25. 
When the questionable and almost inefficient use of anti-
biotics against bacterial infections from biofilm is added, 
it becomes evident that a return to the drawing board is 
needed and the relations in microbiocenosis, in which bac-
teria have a powerful and well-known enemy – the bacte-
riophage, need closer attention. Let us then look at how 
bacteriophage may aid science and medicine to regain bal-
ance and to provide the human race with a carefree life 
and progress.
A Natural Antibiotic – The Return  
of the Bacteriophage
As always, when we cannot solve existing problems in 
the usual way, we look for a solution by going back to the 
drawing board. Luckily, we do not have to go back to the 
very beginning because there are enough knowledge, ex-
perience, and results which claim that bacteriophages can 
be considered in the change of treating bacterial and viral 
diseases38,39. If we remember the limitations and obstacles 
to treating diseases with antibiotics, it will become evident 
that these problems occur because bacteria acquire new 
attributes. Via transformation, transduction, and conjuga-
tion – the mechanisms of gene recombination, bacteria 
acquire the ability to respond to antibiotics since they are 
not as adjusted and reshaped as bacteria, i.e., antibiotics 
are outdated answers. 
Bacteriophages are similar to viruses; they can modify 
their genome twice as fast as prokaryote cells. Treating 
bacterial diseases on the principle of parasitic antibiosis 
with the aid of phage preceded the use of antibiotics. There-
fore, only the principle of mimicking natural balance can 
offer incessant search for new right answers. Bacterio-
phages decipher bacteria molecule’s signals in biofilm, hy-
drolyze the intercellular barrier by disintegrating the ex-
tracellular polymeric substances (EPS), adhere to 
bacterial receptors and “infiltrate” their genes into bacte-
rial protoplasm, and may even disintegrate the protein-
protective mechanism in the bacteria itself40. 
In vitro studies of phage relationship on plankton and 
biofilm cells confirm that the selected course is correct, and 
the use of bacterial phage in the prevention of biofilm for-
mation on endoprosthesis and catheters suggests a possible 
effective use of phage in vivo. Ethical committees allow the 
application of bacteriophage in the treatment of animals 
and humans in the terminal phases of infections with 
multi-resistant types of bacteria. Due to a series of ethical 
and moral doubts, such application is termed a test, not a 
treatment for prudential reasons. 
By declaring that bacteriophage preparations are a 
drug, their application is additionally prevented without 
clinical trials which are too short and too expensive in the 
search for radical change in the accustomed way of treat-
ment of some bacterial diseases41,42. It is to be believed that 
despite some justified, but also some unjustified limita-
tions, the most optimal solutions will be found because 
everything else would lead to an increasingly likely defeat 
against more and more serious forms of a significant por-
tion of bacterial diseases and infections.
Phage is very effective in treating animals, especially 
fish and poultry, even for industrial purposes, for plant 
pathogens growth control (bio-controllers), and in food pro-
tection before conservation38,43–46 (Table 1). Experience out-
side of human application has significantly contributed to 
the so-called Declaration of Helsinki in 2005, under which 
bacteriophage therapy is permitted on humans and ani-
mals for experimental treatment47. Phage therapy allows 
the treatment of many bacterial infections that have not yet 
been overcome by the use of traditional pharmacologic 
agents14,48.  Some examples of phage application for human 
and animal treatment or use in preventive protection of 
endoprosthesis, catheter, and other areas that can be con-
taminated by biofilms illustrate current experience and 
knowledge of real possibilities and directions in the treat-
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ment and prevention of bacterial and viral diseases7,49. 
(Table 1)
The problems of phage treatment are that they are rec-
ognized by the immune system as foreign matter, and are 
not able to reproduce with ease. Thus, phage does not suc-
ceed in multiplying by a large enough number to infect a 
sufficient number of bacteria. On the other hand, phage is 
not used as often largely due to the pharmaceutical indus-
TABLE 1
LIST OF COMPANIES THAT PUBLISH THE USE OF BACTERIOPHAGE AS BASIC TECHNOLOGY69
Company name Country Website 
Preclinical phage therapy research and development
1. AmpliPhi Biosciences SAD www.ampliphibio.com
2. Enbiotix SAD www.enbiotix.com
3. Fixed Phage UK www.fixed-phage.com
4. InnoPhage Portugal www.innophage.com
5. Intralytix SAD www.intralytix.com
6. Pherecydes Pharma France www.pherecydes-pharma.com
7. Technophage Portugal www.technophage.pt
The development of products competent phages
8. AvidBiotics SAD www.avidbiotics.com
9. Eligo Bioscience France http://eligo.bio/  
10. Enbiotix SAD www.enbiotix.com
11. Phico UK www.phicotx.co.uk
Phage product distribution 
12. Biochimpharm Georgia  http://biochimpharm.ge/ 
13. Imbio Russia http://home.mts-nn.ru/~imbio/ 
Patient phage therapy
14. Center for Phage Therapy Poland www.iitd.pan.wroc.pl/en 
15. Eliava Phage Therapy Center Georgia http://eliavaphagetherapy.com/ 
16. Phage Therapy Center Georgia www.phagetherapycenter.com 
17. Phage International SAD www.phageinternational.com 
Phage-mediated biocontrol
18. APS Biocontrol UK http://apsbiocontrol.com/ 
19. Epibiome SAD www.epibiome.com
20. Intralytix SAD www.intralytix.com
21. Omnilytics SAD www.omnilytics.com
22. Phage Biotech Israel www.phage-biotech.com 
23. Phagelux China www.phagelux.com
24. Technophage Portugal www.technophage.pt
Phage lysate products
25. Delmont SAD https://delmontlabs.com/ 
Development of enzybiotics
26. GangaGen SAD/India www.gangagen.com
27. Lysando GmbH Germany www.lysando.com 
28. New Horizons Diagnostics SAD www.nhdiag.com
Phage-based bacterial detection technologies
29. Sample6 SAD www.sample6.com 
Phage-associated industrial contamination 
30. Phage Consultants Poland www.phageconsultants.com 
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try where antibiotic production is increasing even at the 
expense of large investments in research and synthesis of 
new types50. 
Phagotherapy is a term that will be used in further 
consideration as it implies a variety of procedures that are 
used in chemotherapy, radiotherapy, which are usually 
used in treatment51. The name of the drug is phage, and 
the bacteriophage, in the strict sense, will be referred to 
as therapeutic phage (lithic phage).
Clinical Application of Bacteriophage
Resistance of some gram-negative bacteria (P. aerugi-
nosa, E. coli, Klebsiella) and some gram-positive ones (S. 
aureus, Streptococcus sp, Enterococcus), as a cause of se-
vere diseases and septic states, was provoked, among 
other things, by inadequate and unsuitable therapeutic 
doses, mutation ability, or as a result of the difficult cir-
cumstances of treatment of immunocompromised pa-
tients52. These are causal reactions which significantly 
reduce the overall resistance of infected patients and in-
crease their likelihood of secondary infections with the 
same resistant types. The application of phagotherapy is 
already apparent today in people with diabetes infected 
with MRSA, those infected with Burkholderia cepacia 
(BCC), and those suffering from cystic fibrosis (CF)53–56.  
Cystic fibrosis is a disease of the lower respiratory sys-
tem with chronic duration, and it is genetically condi-
tioned57. CF is a result of the mutation of the CFTR (cystic 
fibrosis transmembrane conductance regulator) gene with 
more than 1,500 known mutations. The most common re-
sult is the loss of amino acid phenylalanine in the protein 
regulating the transport of chlorine through the cell mem-
brane58. Due to this process, a very viscous and sticky 
secretion occurs in the lower airways and prevents normal 
coughing and removal of bacteria. In such patients, there-
fore, infections with gram-negative bacteria are very com-
mon, predominantly with Pseudomonas aeruginosa59. It 
has been shown that the cause of these infections is Bur-
kholderia cepacia, also a gram-negative bacteria, which 
is also resistant to antibiotics60. BCC infections are the 
second leading cause of death among hospital patients (the 
mortality rate is around 20% in Canada)61. It spreads rap-
idly among lying patients, especially patients suffering 
from CF, and in the acute phase it results in septicemia, 
heart failure, and significantly reduces life expectancy. 
Phagotherapy was performed on mice infected with iso-
lated strains of BCC from immunocompromised patients 
with cystic fibrosis. Isolated strains of BCC are highly 
resistant to antibiotics, and completely to rifampicin, am-
picillin, cefepime, and others62.
Inflammation of B. cepacia and phagotherapy using 
the aerosol in the lung was first performed with several 
different phages54. Aerosol B. cepacia was applied 24 
hours before the aerosol phage, and two days after treat-
ment, significant and dramatic reduction in the number 
of bacteria (logarithmic reduction rate) was observed. Be-
fore infection, the mice were immunocompromised with 
cyclophosphamide (CPA) which causes leukopenia, and 
the significant reduction of B. cepacia could not be attrib-
uted to the immune system of the host63. Phage therapy 
in mice infected with BCCs strains from patients with CF 
is very effective and could be applied to humans.
In mice, co-therapy of lithic bacteriophage and line-
zolid were also implemented in the treatment of diabetic 
foot infection caused by MRSA56. In annual diabetic pa-
tients, there is a chance that the “diabetic foot” disease 
will occur in 1%, and the pathogenesis mechanism in-
cludes neuropathies, infections, and ischemia. The person 
with diabetes does not feel pain in the area of the lesion, 
and the anti-inflammatory response of the organism is 
suppressed, making patients aware of infection only at the 
wound drainage stage64. Exceedingly wide-spread mixed 
type infections are a major problem because the cause of 
the infection is very often resistant (multi-resistant). One 
of the most common causes is MRSA.
A very effective antibiotic – linezolid (oxazolidinone)64 
can be used for the treatment of MRSA purulent infections 
in the heel for diabetics, and the experiment was intended 
to confirm the existence of a similar agent – the therapeu-
tic phage, which is best suited for in vivo administration56. 
This research was also performed on mice. The rear heels 
of diabetic mice were infected with MRSA clinical isolates, 
identified by gram response and biochemical probes. Ther-
apeutic phage MR-10 was injected into the rear foot of 
diabetic mice. Chhibber et al., through this study demon-
strated the efficacy of phage and antibiotic linezolid ther-
apy56. Pharyngeal and linezolid therapy gives the best 
results, and it is possible to conclude that combined ther-
apy reduces the occurrence of resistance, simplifies and 
reduces the application. Also, it has been shown that 
phages allow antibiotics to be more effective, i.e., they ac-
celerate their entry into the bacteria and thus become an 
effective alternative to the treatment of MRSA infections 
in people with diabetes.
This experience of in vivo co-therapy is consistent with 
in vitro experiments on the combined effect of bacterio-
phage and antibiotics on resistant strains of E. coli and P. 
aeruginosa in particularly hard conditions - in biofilm65. 
Biofilm is a community of prokaryotic cells coated with 
the extracellular polymer matrix. It is protected from an-
timicrobial drugs and acts as a matrix for the establish-
ment and development of slow-growing subpopulations of 
resistant bacteria and specific gene expression66. In order 
to reduce the risk of developing resistant cells, combined 
therapy is often used. This primarily refers to the combi-
nation of multiple antibiotics (tobramycin + clarithromy-
cin, daptomycin + clarithromycin). Likewise, phage cock-
tail used as pre-treatment can significantly reduce the 
development of biofilm66. Combinations of antibiotics and 
phage in therapy more effectively prevent the development 
of biofilms or reduce already formed biofilm matrix for one 
to two logarithms66. There are no reports of resistance in 
biofilm treated with phage and antibiotic combination.
Study of co-therapy of bacteriophage and the antibiotic 
tobramycin on the biofilm of mixed culture of E. coli and 
P. aeruginosa has shown that such combined treatment 
reduces the number of resistant bacteria65. E. coli and P. 
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aeruginosa cultures were used, T4 bacteriophage was 
used to infect E. coli, and bacteriophage PB-1 was used to 
infect P. aeruginosa. Tobramycin was used as the antibi-
otic. Tobramycin is an aminoglycoside bactericide derived 
from Streptomyces tenebrarius, (tetrasaccharide struc-
tures, streptamine structures). It is an inhibitor of bacte-
rial protein synthesis and an inactivator of microbial en-
zymes. It is more effective against gram-negative bacteria, 
but in a broader spectrum also against some gram-positive 
bacteria66. Coulter et al. have shown that phage and anti-
biotics act to reduce resistant bacteria. In monoculture of 
E. coli treated with tobramycin or T4 phage, the reduction 
is about 39%, and their combination reduces the number 
of resistant bacteria by 99%65. In monoculture of P. aeru-
ginosa, the individual reductions for both T4  phage and 
tobramycin are about 60%, while their combination re-
duces the number of resistant bacteria by about 99%65. 
Since the study was conducted in pure bacterial cultures, 
the conclusion should also include the results of the com-
bined effect of tobramycin and the associated specific 
therapeutic phage for treatment in polymicrobial biofilm 
infection.
In some studies, it has been observed that in biofilms 
with mixed cultures, specific phages are not fully effective, 
probably due to the different types of EPS produced by 
those types, and the specific phage does not have an effec-
tive response to that nonhomogeneous matrix. This is why 
the research done in the Qvin Astrid military hospital in 
Belgium on patients with colonized burns is very insight-
ful67. Infected wounds were treated with phage cocktail 
(phage active against P. aeruginosa and S. aureus). In 
controlled conditions, the examination was conducted on 
9 persons and 10 burns. Selected phage cocktail BFC-1 
intended for the treatment of P. aeruginosa and S. aureus 
(phage from the families Myoviridae, Podoviridae, and 
ISP Myoviride) was at a concentration of 109 units/ml pu-
rified from endotoxin. Previously classical bacteriological 
identification had established that the wounds were in-
fected with P. aeruginosa and S. aureus. Directly before 
applying BFC-1 phage to the colonized burns, the wounds 
were divided into two equal parts, one half being treated 
with standard therapy. Thus, patients with suspected 
MDR strains of P. aeruginosa received amikacin in com-
bination with ceftazidime and meropenem, and patients 
with suspected MDR strains of S. aureus were treated 
with vancomycin and linezolid. The other half of the same 
patients’ wounds were treated with BFC-1 phage cocktail 
at 1 ml sterile and endotoxin purified by spraying system 
and on average 0.03ml per square centimeter of the wound 
(or about 107 phages). The surface of the wounds was ap-
proximately 95 cm2 on average, and after 2 to 3 hours the 
biopsy was performed on each. After the initial coloniza-
tion of the wounds from the homogenized sample after the 
final biopsy, taken after the BFC-1 phage treatment, only 
a small bacterial load was observed while unchanged bac-
terial loads were observed in wounds treated with antibi-
otics. Rose et al. undoubtedly confirmed the effectiveness 
of phagotherapy on burns68.
Conclusion
The question is whether phage can be the second line 
of defense, the line that all the more powerful pathogens 
cannot overcome? Of course they can, because their desir-
able and positive effect is incomparably greater than the 
possible unwanted consequences. Science is constantly 
discovering new forms and preparations of phagotherapy, 
gene therapy, antibiotic co-therapy, diagnostics, disinfec-
tion, decontamination, and neutralization of biological 
toxins. The ability to self-duplicate, the specificity of ac-
tion, the harmlessness, the high degree of desirable muta-
tion, and availability obligate scientists to carefully study 
the relationship between humans, diseases, and treatment 
(phage), as well as insufficiently clear in vivo dynamics of 
phage, immune response, and activation of defense mech-
anisms. It is obvious that the main principle of nature is 
to find d answers in the same place where questions arise.
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OD BAKTERIOFAGA DO ANTIBIOTIKA I NAZAD
S A Ž E T A K
Evolucija je životu kao fenomenu, dodijelila bezbrojne oblike i mogućnosti opstanka i nastajanja. Danas su poznati go-
tovo svi mehanizmi odnosa čovjeka s vrha evolucijske ljestvice s mikroorganizmima koji su na njezinom početku. Očuvati 
zdravlje, odnosno život, nije više samo instinktivni odgovor na ugrozu, nego smišljeno stvaranje i korištenje znanja. U 
okolnostima velikih epidemija i ratova koji stvaraju veliku patnju, primijenjena su iskustva tih odnosa čovjek-bolest 
(uzročnik) pa tako bilježimo uporabu bakteriofaga u Poljskoj i Rusiji prije i za vrijeme Drugog svjetskog rata, a gotovo is-
tovremeno uvedena je i antibiotska terapija. Budući da su bakteriofagi – virusi „pratili“ evoluciju bakterija, mehanizam 
njihovog djelovanja počiva na prokariotskoj stanici, pa time jesu neopasni za eukariotsku stanicu ljudskog parenhima. Bilo 
je dakle potrebito samo vratiti ta iskustva u današnje vrijeme kada smo se uvjerili da bakterije imaju na izboru neiscrpan 
vlastiti genski i fenotipski rezistencijski mehanizam. Antibiotici i dalje predstavljaju temelj očuvanja zdravlja, ali sada u 
kombiniranom djelovanju sa specifičnim virusima – bakteriofagima koje možemo proizvesti i primijeniti u okolnostima 
multirezistencije, ali i za pripremu novih farmakoloških pripravaka. Dakle, okrenimo se tim novim znanjima i mogućnostima 
„sve do novog modela antibiotik-bakteriofag“.
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